Literature DB >> 16679492

Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene.

R H Lekanne Deprez, J J Muurling-Vlietman, J Hruda, M J H Baars, L C D Wijnaendts, I Stolte-Dijkstra, M Alders, J M van Hagen.   

Abstract

BACKGROUND: Idiopathic (primary) hypertrophic cardiomyopathy (HCM) is mainly caused by mutations in genes encoding sarcomeric proteins. One of the most commonly mutated HCM genes is the myosin binding protein C (MYBPC3) gene. Mutations in this gene lead mainly to truncation of the protein which gives rise to a relatively mild phenotype. Pure HCM in neonates is rare and most of the time childhood HCM occurs in association with another underlying condition.
OBJECTIVE: To study the presence of mutations in the MYBPC3 gene in idiopathic childhood HCM.
METHODS: MYBPC3 coding region and splice junction variation were analysed by denaturing high performance liquid chromatography (DHPLC) and sequencing in DNA isolated from two neonates with severe unexplained HCM, who died within the first weeks of life.
RESULTS: Truncating mutations were found in both alleles of the MYBPC3 gene in both patients, suggesting there was no functional copy of the MYBPC3 protein. Patient 1 carried the maternally inherited c.2373_2374insG mutation and the paternally inherited splice-donor site mutation c.1624+1G-->A. Patient 2 carried the maternally inherited frameshift mutation c.3288delA (p.Glu1096fsX92) and the paternally inherited non-sense mutation c.2827C-->T (p.Arg943X).
CONCLUSIONS: The findings indicate the need for mutation analysis of genes encoding sarcomeric proteins in childhood HCM and the possibility of compound heterozygosity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16679492      PMCID: PMC2563166          DOI: 10.1136/jmg.2005.040329

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  19 in total

1.  Sensitivity and accuracy of quantitative real-time polymerase chain reaction using SYBR green I depends on cDNA synthesis conditions.

Authors:  Ronald H Lekanne Deprez; Arnoud C Fijnvandraat; Jan M Ruijter; Antoon F M Moorman
Journal:  Anal Biochem       Date:  2002-08-01       Impact factor: 3.365

Review 2.  Phenotypic diversity in hypertrophic cardiomyopathy.

Authors:  Michael Arad; J G Seidman; Christine E Seidman
Journal:  Hum Mol Genet       Date:  2002-10-01       Impact factor: 6.150

3.  Sarcomeric genotyping in hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Steve R Ommen; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman
Journal:  Mayo Clin Proc       Date:  2005-04       Impact factor: 7.616

4.  Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice.

Authors:  Samantha P Harris; Christopher R Bartley; Timothy A Hacker; Kerry S McDonald; Pamela S Douglas; Marion L Greaser; Patricia A Powers; Richard L Moss
Journal:  Circ Res       Date:  2002-03-22       Impact factor: 17.367

Review 5.  Hypertrophic cardiomyopathy: a systematic review.

Authors:  Barry J Maron
Journal:  JAMA       Date:  2002-03-13       Impact factor: 56.272

6.  A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance.

Authors:  J A Moolman; S Reith; K Uhl; S Bailey; M Gautel; B Jeschke; C Fischer; J Ochs; W J McKenna; H Klues; H P Vosberg
Journal:  Circulation       Date:  2000-03-28       Impact factor: 29.690

7.  Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy.

Authors:  Pascale Richard; Philippe Charron; Lucie Carrier; Céline Ledeuil; Theary Cheav; Claire Pichereau; Abdelaziz Benaiche; Richard Isnard; Olivier Dubourg; Marc Burban; Jean-Pierre Gueffet; Alain Millaire; Michel Desnos; Ketty Schwartz; Bernard Hainque; Michel Komajda
Journal:  Circulation       Date:  2003-04-21       Impact factor: 29.690

8.  The incidence of pediatric cardiomyopathy in two regions of the United States.

Authors:  Steven E Lipshultz; Lynn A Sleeper; Jeffrey A Towbin; April M Lowe; E John Orav; Gerald F Cox; Paul R Lurie; Kristina L McCoy; Melissa A McDonald; Jane E Messere; Steven D Colan
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

9.  The epidemiology of childhood cardiomyopathy in Australia.

Authors:  Alan W Nugent; Piers E F Daubeney; Patty Chondros; John B Carlin; Michael Cheung; Lynette C Wilkinson; Andrew M Davis; Stephen G Kahler; C W Chow; James L Wilkinson; Robert G Weintraub
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

10.  Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy.

Authors:  J Erdmann; S Daehmlow; S Wischke; M Senyuva; U Werner; J Raible; N Tanis; S Dyachenko; M Hummel; R Hetzer; V Regitz-Zagrosek
Journal:  Clin Genet       Date:  2003-10       Impact factor: 4.438

View more
  33 in total

Review 1.  Nuclear cardiac imaging in hypertrophic cardiomyopathy.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

2.  Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.

Authors:  I Christiaans; E A Nannenberg; D Dooijes; R J E Jongbloed; M Michels; P G Postema; D Majoor-Krakauer; A van den Wijngaard; M M A M Mannens; J P van Tintelen; I M van Langen; A A M Wilde
Journal:  Neth Heart J       Date:  2010-05       Impact factor: 2.380

3.  Clinical utility gene card for: hypertrophic cardiomyopathy (type 1-14).

Authors:  Yigal M Pinto; Arthur Aam Wilde; Ingrid Aw van Rijsingen; Imke Christiaans; Ronald H Lekanne Deprez; Perry M Elliott
Journal:  Eur J Hum Genet       Date:  2011-01-26       Impact factor: 4.246

Review 4.  Linking myofilaments to sudden cardiac death: recent advances.

Authors:  Sabine Huke
Journal:  J Physiol       Date:  2017-03-16       Impact factor: 5.182

Review 5.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

Review 6.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

7.  Dissociation of structural and functional phenotypes in cardiac myosin-binding protein C conditional knockout mice.

Authors:  Peter P Chen; Jitandrakumar R Patel; Patricia A Powers; Daniel P Fitzsimons; Richard L Moss
Journal:  Circulation       Date:  2012-07-24       Impact factor: 29.690

8.  Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects.

Authors:  Marja W Wessels; Johanna C Herkert; Ingrid M Frohn-Mulder; Michiel Dalinghaus; Arthur van den Wijngaard; Ronald R de Krijger; Michelle Michels; Irenaeus Fm de Coo; Yvonne M Hoedemaekers; Dennis Dooijes
Journal:  Eur J Hum Genet       Date:  2014-10-22       Impact factor: 4.246

Review 9.  Strategies for targeting the cardiac sarcomere: avenues for novel drug discovery.

Authors:  Joshua B Holmes; Chang Yoon Doh; Ranganath Mamidi; Jiayang Li; Julian E Stelzer
Journal:  Expert Opin Drug Discov       Date:  2020-02-18       Impact factor: 6.098

Review 10.  A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management.

Authors:  Kyla E Dunn; Colleen Caleshu; Allison L Cirino; Carolyn Y Ho; Euan A Ashley
Journal:  Circ Cardiovasc Genet       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.